<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>PharmaAsia - Drug Manufacturing</title><link>http://www.pharmaasia.com</link><description>PharmaAsia - Drug Manufacturing</description><language>en-US</language><copyright>Copyright 2012 Ten Alps Communications Asia. All rights reserved.</copyright><pubDate>Thu, 9 Feb 2012 19:21:01 +0800</pubDate><item><title>Life Technologies appoints president of medical sciences</title><link>http://www.pharmaasia.com/article/life-technologies-appoints-president-of-medical-sciences/9325</link><description>Life Technologies announced that Ronnie Andrews, former CEO of Clarient and Segment Leader, GE Molecular Diagnostics, has joined the company as president, medical sciences.</description><guid>http://www.pharmaasia.com/article/life-technologies-appoints-president-of-medical-sciences/9325</guid><pubDate>Fri, 10 Feb 2012 00:00:00 +0800</pubDate></item><item><title>Novozymes Biopharma wins technology innovation award</title><link>http://www.pharmaasia.com/article/novozymes-biopharma-wins-technology-innovation-award/9323</link><description>Novozymes Biopharma has received the 2012 Drug Delivery Partnerships (DDP) Technology Innovation award for the company’s half-life extension platform. The award recognizes the most exciting delivery technology of the year.</description><guid>http://www.pharmaasia.com/article/novozymes-biopharma-wins-technology-innovation-award/9323</guid><pubDate>Wed, 8 Feb 2012 00:00:00 +0800</pubDate></item><item><title>MabCure signs license agreement with Biotech Investment Corp</title><link>http://www.pharmaasia.com/article/mabcure-signs-license-agreement-with-biotech-investment-corp/9322</link><description>MabCure has signed a license agreement with Biotech Investment Corp. (Biotech), a Nevada-based biotechnology investment company.  The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer.   In addition to the license fee paid to MabCure, Biotech will issue to MabCure 15 percent of its outstanding shares on a fully diluted basis and will pay a royalty of 12.5 percent on revenues.</description><guid>http://www.pharmaasia.com/article/mabcure-signs-license-agreement-with-biotech-investment-corp/9322</guid><pubDate>Tue, 7 Feb 2012 00:00:00 +0800</pubDate></item><item><title>Agilent Technologies’s Thought Leader Award supports Chris Evelo’s work at Maastricht University</title><link>http://www.pharmaasia.com/article/agilent-technologies-s-thought-leader-award-supports-chris-evelo-s-work-at-maastricht-university/9321</link><description>Agilent Technologies the Agilent Technologies Foundation announced that Dr Chris Evelo and the department of bioinformatics at Maastricht University are the recipients of an Agilent Thought Leader Award supporting development of software to integrate different types of biological data. The goal of this award is to help accelerate breakthroughs in disease research by facilitating integrative systems biology approaches.</description><guid>http://www.pharmaasia.com/article/agilent-technologies-s-thought-leader-award-supports-chris-evelo-s-work-at-maastricht-university/9321</guid><pubDate>Mon, 6 Feb 2012 00:00:00 +0800</pubDate></item><item><title>Boehringer Ingelheim single combination of telmisartan and amlodipine provides 24-hour blood pressure reduction and control</title><link>http://www.pharmaasia.com/article/boehringer-ingelheim-single-combination-of-telmisartan-and-amlodipine-provides-24-hour-blood-pressure-reduction-and-control/9319</link><description>Boehringer Ingelheim has released a new anti-hypertensive drug (TWYNSTA) containing a unique combination of telmisartan and amlodipine. Very often, hypertension sufferers take up to four drugs to reach an acceptable blood pressure (BP) more effectively. The single-pill combination drug is taken once daily and provides additional therapeutic and cardiovascular (CV) benefits.</description><guid>http://www.pharmaasia.com/article/boehringer-ingelheim-single-combination-of-telmisartan-and-amlodipine-provides-24-hour-blood-pressure-reduction-and-control/9319</guid><pubDate>Thu, 2 Feb 2012 00:00:00 +0800</pubDate></item><item><title>Werum’s MES PAS-X is part of Novo Nordisk’s first combined ERP/MES system</title><link>http://www.pharmaasia.com/article/werum-s-mes-pas-x-is-part-of-novo-nordisk-s-first-combined-erp-mes-system/9318</link><description>In the framework of the global PS@SAP program, Accenture, Werum Software &amp; Systems, and NNE Pharmaplan have rolled out the first combined ERP/MES system at Novo Nordisk’s site in Denmark.</description><guid>http://www.pharmaasia.com/article/werum-s-mes-pas-x-is-part-of-novo-nordisk-s-first-combined-erp-mes-system/9318</guid><pubDate>Wed, 1 Feb 2012 00:00:00 +0800</pubDate></item><item><title>Porex expands chromatography, SPE media offerings</title><link>http://www.pharmaasia.com/article/porex-expands-chromatography-spe-media-offerings/9309</link><description>Porex has enhanced its comprehensive line of  chromatography and SPE Media solutions with versatile, high-performance porous materials and filters designed to endure the most challenging chromatography applications.</description><guid>http://www.pharmaasia.com/article/porex-expands-chromatography-spe-media-offerings/9309</guid><pubDate>Tue, 31 Jan 2012 00:00:00 +0800</pubDate></item><item><title>Drug Process Licensing Associates launches pharma database</title><link>http://www.pharmaasia.com/article/drug-process-licensing-associates-launches-pharma-database/9308</link><description>PHILL, which stands for PHarmaceutical InteLLigence, is a database of bulk drug and intermediates producer information pertinent to members of the chemical and pharmaceutical industry. It also includes regulatory information such as Drug Master Files, Veterinary Master Files, Certificates of Suitability and Drug Approvals.</description><guid>http://www.pharmaasia.com/article/drug-process-licensing-associates-launches-pharma-database/9308</guid><pubDate>Fri, 27 Jan 2012 00:00:00 +0800</pubDate></item><item><title>Sartorius Stedim Biotech, Refine Technology announce cooperation</title><link>http://www.pharmaasia.com/article/sartorius-stedim-biotech-refine-technology-announce-cooperation/9310</link><description>This joint development project proactively responds to the current market demand for more effective connectivity between equipment from different suppliers to enable development of efficient, streamlined systems.</description><guid>http://www.pharmaasia.com/article/sartorius-stedim-biotech-refine-technology-announce-cooperation/9310</guid><pubDate>Thu, 26 Jan 2012 00:00:00 +0800</pubDate></item><item><title>Molecular Profiles invests in new facility to increase manufacturing capabilities for clinical trials</title><link>http://www.pharmaasia.com/article/molecular-profiles-invests-in-new-facility-to-increase-manufacturing-capabilities-for-clinical-trials/9304</link><description>Molecular Profiles, a leading specialist contract research and manufacturing organization, announces the commencement of construction of a new manufacturing facility. This £9 million investment will allow Molecular Profiles to expand its current manufacturing capabilities while strengthening its existing expertise in the drug development field.</description><guid>http://www.pharmaasia.com/article/molecular-profiles-invests-in-new-facility-to-increase-manufacturing-capabilities-for-clinical-trials/9304</guid><pubDate>Thu, 19 Jan 2012 00:00:00 +0800</pubDate></item></channel></rss>

